Our DNA
We enable the next generation of precision medicine
ProteinQure is a clinical-stage biotech company focused on the design of novel exotic peptides with broad therapeutic applications. We recently announced the first clinical trial of a fully AI-designed peptide-drug conjugate in Canada and the United States.
Our approach leverages peptide-drug conjugates to enable precise tissue- and cell-specific delivery of therapeutics. At the core of this innovation is ProteinStudio™, our proprietary computational platform that combines predictive power with deep structural insights into peptides and proteins.
Our platform supports the development of novel strategies for therapeutic payload delivery. Our lead program, PQ203, is currently being evaluated in a Phase 1 clinical trial for advanced solid tumors—marking a milestone in the application of AI to peptide drug design.
Our Platform
ProteinStudio™: The best computational platform for the design of de novo peptides
We have developed ProteinStudio™, an integrated platform of proprietary technologies built to solve complex drug design challenges involving peptides and proteins. ProteinStudio™ harnesses molecular simulations and custom AI models on petascale supercomputers, enabling the creation of unique molecular scaffolds.
Our platform integrates thousands of non-natural amino acids with high-quality in-house assays, enabling the design of unprecedented drug-like peptides from minimal data. Its validation has been demonstrated in vitro and in vivo through pharma partnerships and the advancement of our internal pipeline of tissue-specific delivery assets.
Dare
to Deliver
to Deliver
Tissue-specific delivery peptides
Our proprietary peptides can be used to deliver a variety of therapeutic payloads intracellularly via receptor-mediated endocytosis. Peptide-drug conjugates boast several advantages: they offer unique pharmacokinetics, and are significantly smaller than antibody-drug conjugates, which enables deeper tissue penetration and lower immunogenicity.
By precisely targeting specific tissues and cells, our computationally designed peptides optimize therapeutic efficacy and minimize side effects, setting new standards in precision medicine and transforming treatment approaches.
Tissue specificity and penetration
Redosable and tolerable
Flexible building blocks
Pipeline
Using ProteinStudio™, we have designed high-affinity SORT1-targeting peptides that are capable of delivering therapeutic payloads directly into cancer cells. SORT1 is a compelling new target for oncology: a receptor that mediates efficient endocytosis and lysosomal delivery, found to be enriched across multiple tumor types, including triple-negative breast cancer.
We are developing this system to carry and release various therapeutic payloads, including cytotoxic agents, radioisotopes, and oligonucleotides. We have additional programs in renal and blood brain barrier shuttle biology.
ProteinQure
Redefining Drug Discovery, Together
At ProteinQure, we take pride in our cross-disciplinary team that unites expertise in experimental biology, software engineering, machine learning, and computational biology. This collaborative mindset powers everything we do, allowing us to bridge disciplines and tackle some of the toughest challenges in drug discovery.
Our company brings together world-class science and technology with a bold vision for the future of medicine. Discover more about who we are, meet the team shaping the future of peptide therapeutics, and explore opportunities to join us.